- Home
- Publications
- Publication Search
- Publication Details
Title
Pathogenesis and management of myeloma bone disease
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 2, Issue 4, Pages 385-398
Publisher
Informa UK Limited
Online
2009-08-13
DOI
10.1586/ehm.09.36
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
- (2008) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
- (2008) Y.-W. Qiang et al. BLOOD
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases
- (2008) Kan Yonemori et al. CANCER SCIENCE
- Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
- (2008) Martin Kaiser et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment
- (2008) Ulrike Heider et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
- (2008) Deborah J Heath et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*
- (2008) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
- (2008) Ashraf Badros et al. JOURNAL OF CLINICAL ONCOLOGY
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
- (2008) E Terpos et al. LEUKEMIA
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
- (2008) Vittorio Montefusco et al. LEUKEMIA & LYMPHOMA
- Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions
- (2008) P. Boissy et al. LEUKEMIA RESEARCH
- KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling
- (2008) Rentian Feng et al. MOLECULAR CANCER THERAPEUTICS
- Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study
- (2008) A. S. Mudano et al. OSTEOPOROSIS INTERNATIONAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation